First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
Recruiting · NCT06840782 · Registry updated 2025-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. | Oligometastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | Phase 3 | 2025-09-15 | NCT06840782 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris | 93 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Sainte-Catherine | Avignon | France | 1 |
| Gustave Roussy | Villejuif | France | 2 |
| Institut de Radiothérapie du Sud de l'Oise | Creil | France | 1 |